Actively Recruiting
Gepant treAtments: EffectIveNess and tolERability (GAINER)
Led by University of Florence · Updated on 2026-01-21
100
Participants Needed
2
Research Sites
169 weeks
Total Duration
On this page
Sponsors
U
University of Florence
Lead Sponsor
I
IRCCS National Neurological Institute "C. Mondino" Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
CONDITIONS
Official Title
Gepant treAtments: EffectIveNess and tolERability (GAINER)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).
- At least 3 migraine days per month (MMDs).
- Good compliance to study procedures.
- Availability of headache diary for at least the month before enrollment.
You will not qualify if you...
- Contraindications for use of gepants.
- Medical diseases or comorbidities that might interfere with study assessments.
- Medical comorbidities that could affect study results.
- Pregnancy and breastfeeding.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
Florence, Italy, 50134
Actively Recruiting
2
IRCCS National Neurological Institute "C. Mondino" Foundation
Pavia, Italy, 27100
Actively Recruiting
Research Team
L
Luigi F Iannone, MD
CONTACT
R
Roberto De Icco, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here